SEVUparin as a potential Adjunctive Treatment in children with severe malaria: A phase I trial safety and dose finding trial (SEVUSMAART)

Background Even on the best antimalarial treatments (injectable artesunate) African children with severe malaria have poor outcomes with most deaths occurring early in the course of hospital admission (<24hours). Lactic acidosis, largely due to impairment of the microcirculatory flow due to parasite sequestration, is a main risk factor for poor outcome. There are no adjuvant treatments for severe malaria that target this complication. Sevuparin, a heparin-like drug, binds to Plasmodium falciparum erythrocyte membrane protein blocking merozoite invasion, preventing cytoadherence and transiently de-sequestering infected erythrocytes. Leading to improved microcirculatory flow by reversing/preventing parasite sequestration. If given early during admission this could result in improvements in outcomes . Sevuparin has been shown to be safe and well tolerated in adults with only some mild transient effects on activated partial thromboplastin time (APTT) were reported, without clinical consequences. Methods A Phase I trial designed to provide data on safety, dosing, feasibility of sevuparin as an adjuvant therapy in Kenya and Zambian children with severe malaria complicated by lactic acidosis (> 2mmol/l). Three intravenous doses will be given at admission (0 hours), 8 and 16 hours. APPT will be measured 1 hour after each dose (to assess maximum toxicity). Studying 20 children will allow sufficient data on safety to be generated across a range of doses to identify the maximum tolerated dose (MTD) using the Continual Reassessment Method, which adapts or informs subsequent doses for each child based on the data from previously enrolled children. The MTD will be identified based on the dose-toxicity model updated by each previous patient’s APTT results using standard methods. Conclusions The results of the Phase I trial will identify the final dose to be tested in a Phase II trial in terms of both efficacy and safety outcomes. Registration PACTR number: 202007890194806 (date 20/07/2020) ISRCTN32271864 (date 28/07/2021)

[1]  M. Munir,et al.  Heparin in the treatment of cerebral malaria. , 2021, Paediatrica Indonesiana.

[2]  D. Harrison,et al.  Randomised controlled trial of oxygen therapy and high-flow nasal therapy in African children with pneumonia , 2021, Intensive Care Medicine.

[3]  B. Biemond,et al.  Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. , 2021, The Lancet. Haematology.

[4]  K. Maitland,et al.  Immediate Transfusion in African Children with Uncomplicated Severe Anemia. , 2019, The New England journal of medicine.

[5]  K. Maitland,et al.  Transfusion Volume for Children with Severe Anemia in Africa. , 2019, The New England journal of medicine.

[6]  K. Maitland,et al.  Lactate clearance as a prognostic marker of mortality in severely ill febrile children in East Africa , 2018, BMC Medicine.

[7]  M. Wahlgren,et al.  Inhibition of merozoite invasion and transient de-sequestration by sevuparin in humans with Plasmodium falciparum malaria , 2017, PloS one.

[8]  A. Noor,et al.  The global fight against malaria is at crossroads , 2017, The Lancet.

[9]  Robert W. Snow,et al.  The prevalence of Plasmodium falciparum in sub Saharan Africa since 1900 , 2017, Nature.

[10]  M. Wahlgren,et al.  Effects of sevuparin on rosette formation and cytoadherence of Plasmodium falciparum infected erythrocytes , 2017, PloS one.

[11]  K. Maitland,et al.  High Frequency of Blackwater Fever Among Children Presenting to Hospital With Severe Febrile Illnesses in Eastern Uganda , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  Richard J. Maude,et al.  Defining Surrogate Endpoints for Clinical Trials in Severe Falciparum Malaria , 2017, PloS one.

[13]  K. Maitland.  Severe Malaria in African Children - The Need for Continuing Investment. , 2016, The New England journal of medicine.

[14]  A. Laggner,et al.  Point‐of‐care PT and aPTT in patients with suspected deficiencies of coagulation factors , 2016, International journal of laboratory hematology.

[15]  R. Maude,et al.  Sequestration and Red Cell Deformability as Determinants of Hyperlactatemia in Falciparum Malaria , 2015, The Journal of infectious diseases.

[16]  M. Wahlgren,et al.  Binding of Subdomains 1/2 of PfEMP1-DBL1α to Heparan Sulfate or Heparin Mediates Plasmodium falciparum Rosetting , 2015, PloS one.

[17]  K. Maitland.  Management of severe paediatric malaria in resource-limited settings , 2015, BMC Medicine.

[18]  Lucille Blumberg,et al.  Severe Malaria , 2014, Tropical medicine & international health : TM & IH.

[19]  Victor A Alegana,et al.  The changing risk of Plasmodium falciparum malaria infection in Africa: 2000–10: a spatial and temporal analysis of transmission intensity , 2014, The Lancet.

[20]  K. Maitland,et al.  Invasive bacterial co-infection in African children with Plasmodium falciparum malaria: a systematic review , 2014, BMC Medicine.

[21]  A. Craig,et al.  Loss of endothelial protein C receptors links coagulation and inflammation to parasite sequestration in cerebral malaria in African children. , 2013, Blood.

[22]  N. Day,et al.  Lethal Malaria: Marchiafava and Bignami Were Right , 2013, The Journal of infectious diseases.

[23]  K. Silamut,et al.  Defining Falciparum-Malaria-Attributable Severe Febrile Illness in Moderate-to-High Transmission Settings on the Basis of Plasma PfHRP2 Concentration , 2012, The Journal of infectious diseases.

[24]  R. Maude,et al.  Relative contributions of macrovascular and microvascular dysfunction to disease severity in falciparum malaria. , 2012, The Journal of infectious diseases.

[25]  K. Bojang,et al.  Predicting the Clinical Outcome of Severe Falciparum Malaria in African Children: Findings From a Large Randomized Trial , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  Mark J. Ponsford,et al.  Sequestration and microvascular congestion are associated with coma in human cerebral malaria. , 2012, The Journal of infectious diseases.

[27]  K. Maitland,et al.  Mortality after fluid bolus in African children with severe infection. , 2011, The New England journal of medicine.

[28]  K. Maitland,et al.  Use of deferred consent for severely ill children in a multi-centre phase III trial , 2011, Trials.

[29]  M. Wahlgren,et al.  Low anticoagulant heparin disrupts Plasmodium falciparum rosettes in fresh clinical isolates. , 2011, The American journal of tropical medicine and hygiene.

[30]  K. Maitland,et al.  Hypoglycaemia in severe malaria, clinical associations and relationship to quinine dosage , 2010, BMC infectious diseases.

[31]  C. John,et al.  Adjunctive therapy for cerebral malaria and other severe forms of Plasmodium falciparum malaria , 2010, Expert review of anti-infective therapy.

[32]  Mehmet Kocak,et al.  Continual Reassessment Method vs. Traditional Empirically Based Design: Modifications Motivated by Phase I Trials in Pediatric Oncology by the Pediatric Brain Tumor Consortium , 2009, Journal of biopharmaceutical statistics.

[33]  Fonns V Vijver,et al.  Monitoring psychomotor development in a resourcelimited setting: an evaluation of the Kilifi Developmental Inventory , 2008, Annals of tropical paediatrics.

[34]  M. Molyneux,et al.  Plasmodium falciparum‐ infected erythrocytes induce tissue factor expression in endothelial cells and support the assembly of multimolecular coagulation complexes , 2007, Journal of thrombosis and haemostasis : JTH.

[35]  P. Olumese,et al.  Coagulation profile in Nigerian children with cerebral malaria. , 2006, The Nigerian postgraduate medical journal.

[36]  Elizabeth Garrett-Mayer,et al.  The continual reassessment method for dose-finding studies: a tutorial , 2006, Clinical trials.

[37]  B. Lowe,et al.  Changes in white blood cells and platelets in children with falciparum malaria: relationship to disease outcome , 2002, British journal of haematology.

[38]  C. Rogier,et al.  Prognostic value of thrombocytopenia in African children with falciparum malaria. , 2002, The American journal of tropical medicine and hygiene.

[39]  N. White,et al.  Abnormal blood flow and red blood cell deformability in severe malaria. , 2000, Parasitology today.

[40]  M. Wahlgren,et al.  The duffy-binding-like domain 1 of Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) is a heparan sulfate ligand that requires 12 mers for binding. , 2000, Blood.

[41]  T. Taylor,et al.  Cytokine expression in the brain in human cerebral malaria. , 1999, The Journal of infectious diseases.

[42]  S. Fox,et al.  Systemic endothelial activation occurs in both mild and severe malaria. Correlating dermal microvascular endothelial cell phenotype and soluble cell adhesion molecules with disease severity. , 1998, The American journal of pathology.

[43]  M. Wahlgren,et al.  Molecular Aspects of Severe Malaria , 1996, Clinical Microbiology Reviews.

[44]  R. Snow,et al.  Indicators of life-threatening malaria in African children. , 1995, The New England journal of medicine.

[45]  A. Grauer,et al.  Elevated Thrombomodulin Plasma Levels as a Result of Endothelial Involvement in Plasmodium falciparum Malaria , 1994, Thrombosis and Haemostasis.

[46]  U. Raeth,et al.  Serum levels of adhesion molecules and thrombomodulin as indicators of vascular injury in severe Plasmodium falciparum malaria , 1994, The clinical investigator.

[47]  R. Lorenz,et al.  Activation of the coagulation cascade in severe falciparum malaria through the intrinsic pathway , 1994, British journal of haematology.

[48]  F. Ofosu,et al.  Maturation of the hemostatic system during childhood. , 1992, Blood.

[49]  M. Wahlgren,et al.  Effect of different fractions of heparin on Plasmodium falciparum merozoite invasion of red blood cells in vitro. , 1992, The American journal of tropical medicine and hygiene.

[50]  M. Wahlgren,et al.  Disruption of Plasmodium falciparum erythrocyte rosettes by standard heparin and heparin devoid of anticoagulant activity. , 1992, The American journal of tropical medicine and hygiene.

[51]  M. Dietrich,et al.  Neither heparin nor acetylsalicylic acid influence the clinical course in human Plasmodium falciparum malaria: a prospective randomized study. , 1991, The American journal of tropical medicine and hygiene.

[52]  M. Dietrich,et al.  Activation of the host response in human Plasmodium falciparum malaria: relation of parasitemia to tumor necrosis factor/cachectin, thrombin-antithrombin III, and protein C levels. , 1991, The American journal of medicine.

[53]  N. White,et al.  Activation of the coagulation cascade in falciparum malaria. , 1989, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[54]  K. Gyr,et al.  Malaria at the University Hospital and the St.-Clara Hospital, Basel, in the period of 1970-1979. , 1983, Bulletin de la Societe de pathologie exotique et de ses filiales.

[55]  M. Munir,et al.  Heparin in the treatment of cerebral malaria (a preliminary report). , 1976, Paediatrica Indonesiana.

[56]  H. Reid.  ADJUVANT TREATMENT OF SEVERE FALCIPARUM MALARIA, INTRAVASCULAR COAGULATION, AND HEPARIN , 1975, The Lancet.

[57]  H. Reid,et al.  Ancrod, heparin, and -aminocaproic acid in simian Knowlesi malaria. , 1972, Lancet.

[58]  F. Nkrumah,et al.  Fibrin-degradation products in cerebral malaria. , 1972, Lancet.

[59]  M. Eisenhut,et al.  Pre-referral rectal artesunate for severe malaria (Review) , 2014 .

[60]  C. Karema,et al.  Diagnosis, prognosis and treatment of severe falciparum malaria in African children , 2012 .

[61]  C. Ince,et al.  Direct in vivo assessment of microcirculatory dysfunction in severe falciparum malaria. , 2008, The Journal of infectious diseases.

[62]  Weltgesundheitsorganisation.  World malaria report , 2005 .

[63]  S. Kyes,et al.  Antigenic variation at the infected red cell surface in malaria. , 2001, Annual review of microbiology.